<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33017028</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>10</Issue><PubDate><Year>2020</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System.</ArticleTitle><Pagination><StartPage>e2014645</StartPage><MedlinePgn>e2014645</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2014645</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2020.14645</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Using real-world data, the US Department of Veterans Affairs (VA) initiated a surveillance evaluation of edaravone after its approval for amyotrophic lateral sclerosis (ALS) in 2017. The use and safety of edaravone for patients with ALS in the VA health care system remain to be assessed.</AbstractText><AbstractText Label="OBJECTIVE">To describe a pharmacovigilance surveillance initiative with edaravone to monitor patient characteristics, utilization (edaravone cycles and riluzole use), and safety and to evaluate safety/effectiveness.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This propensity score-matched cohort study used data on 369 patients with documented definite or probable ALS in the Veterans Health Administration (VHA) with at least 1 prescription for edaravone between August 1, 2017, and September 30, 2019. The analysis compared edaravone (alone or with riluzole) with riluzole only. For chronic users (&#x2265;6 months of drug), a time-to-event model evaluated ALS-related outcomes, with censoring at outcome, death, or end of evaluation. Patients with Parkinson disease, dementia, schizophrenia, or significant respiratory insufficiency per diagnosis codes within 2 years before prescription initiation were excluded. In overall matched cohorts, 223 patients treated with edaravone were 1:3 propensity score matched based on predefined confounders. For the chronic user subgroup analysis, 96 patients receiving edaravone and 424 patients receiving riluzole only were included.</AbstractText><AbstractText Label="EXPOSURES">Edaravone (alone or with riluzole) vs riluzole only.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Patient characteristics, ALS drug use, and mortality. Acute outcomes (within 6 months of index) included proportion and mean time to event for death, discontinuation, or all-cause hospitalization, and outcomes for chronic users (receiving &gt;6 months of treatment) included hazard ratios of outcomes related to disease-state progression.</AbstractText><AbstractText Label="RESULTS">Of 369 patients who received edaravone, most were older (mean [SD] age, 64.6 [11.3] years), male (346 [93.8%]), and White (261 [70.7%]). As of September 2019, 59.9% of edaravone patients had discontinued treatment; of those, 49.5% (108 of 218) received only 1 to 3 treatment cycles. Approximately 30% (110 patients) died. In a matched evaluation, significantly more acute all-cause hospitalization events occurred with edaravone (35.4% vs 22.0% for riluzole only); 72.6% of the edaravone cohort received edaravone with riluzole. Among chronic users, edaravone patients (70.8% edaravone with riluzole) had an increased hazard ratio of ALS-associated hospitalization (2.51; 95% CI, 1.18-8.16). The death rate was lower with edaravone but the difference was not statistically significant.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Early edaravone discontinuation was common in the VA. Although outcomes favored use of riluzole only in the matched analysis, results should be interpreted with caution, as unmeasured bias in observational data is likely.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vu</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pharmacy Benefits Management Services, Center for Medication Safety, Department of Veterans Affairs, Hines, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Health Equity Research and Promotion, Department of Veterans Affairs, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tortorice</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Pharmacy Benefits Management Services, Department of Veterans Affairs, Hines, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zacher</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pharmacy Benefits Management Services, Department of Veterans Affairs, Hines, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Diane</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Pharmacy Benefits Management Services, Center for Medication Safety, Department of Veterans Affairs, Hines, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hur</LastName><ForeName>Kwan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Pharmacy Benefits Management Services, Center for Medication Safety, Department of Veterans Affairs, Hines, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Rongping</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Pharmacy Benefits Management Services, Center for Medication Safety, Department of Veterans Affairs, Hines, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Good</LastName><ForeName>Chester B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Pharmacy Benefits Management Services, Center for Medication Safety, Department of Veterans Affairs, Hines, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Health Equity Research and Promotion, Department of Veterans Affairs, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Insurance, UPMC Health Plan, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glassman</LastName><ForeName>Peter A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Pharmacy Benefits Management Services, Center for Medication Safety, Department of Veterans Affairs, Hines, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Greater Los Angeles Healthcare System, Department of Veterans Affairs, Los Angeles, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmacy Benefits Management Services, Department of Veterans Affairs, Washington, DC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cunningham</LastName><ForeName>Francesca E</ForeName><Initials>FE</Initials><AffiliationInfo><Affiliation>Pharmacy Benefits Management Services, Center for Medication Safety, Department of Veterans Affairs, Hines, Illinois.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016166">Free Radical Scavengers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>S798V6YJRP</RegistryNumber><NameOfSubstance UI="D000077553">Edaravone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077553" MajorTopicYN="N">Edaravone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016166" MajorTopicYN="N">Free Radical Scavengers</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014728" MajorTopicYN="N">Veterans</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000081324" MajorTopicYN="N">Veterans Health Services</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Vu reported a fellowship scholarship from the Rho Chi Society to support clinical research during the conduct of the study. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>5</Day><Hour>12</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33017028</ArticleId><ArticleId IdType="pmc">PMC7536587</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.14645</ArticleId><ArticleId IdType="pii">2771220</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Veterans Benefits Administration  Presumptive disability benefits. Published November 2018. Accessed January 1, 2020. https://www.benefits.va.gov/BENEFITS/factsheets/serviceconnected/presumption.pdf</Citation></Reference><Reference><Citation>Nelson LM, Topol B, Kaye W, et al. . Estimation of the prevalence of amyotrophic lateral sclerosis in the United States using national administrative healthcare data from 2002 to 2004 and capture-recapture methodology. Neuroepidemiology. 2018;51(3-4):149-157. doi:10.1159/000488798</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000488798</ArticleId><ArticleId IdType="pmc">PMC6250049</ArticleId><ArticleId IdType="pubmed">30092573</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Kaye W, Raymond J, et al. . Prevalence of amyotrophic lateral sclerosis&#x2014;United States, 2015. MMWR Morb Mortal Wkly Rep. 2018;67(46):1285-1289. doi:10.15585/mmwr.mm6746a1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6746a1</ArticleId><ArticleId IdType="pmc">PMC6289079</ArticleId><ArticleId IdType="pubmed">30462626</ArticleId></ArticleIdList></Reference><Reference><Citation>Radicava (edaravone injection). Package insert. Jersey City, NJ: Mitsubishi Tanabe Pharma Corporation; 2018.</Citation></Reference><Reference><Citation>Rilutek (riluzole). Package insert. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; 2012.</Citation></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V; ALS/Riluzole Study Group . A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994;330(9):585-591. doi:10.1056/NEJM199403033300901</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L, Delumeau JC, Bejuit R, Truffinet P, Meininger V; Riluzole/ALS Study Group II . A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol. 2002;249(5):609-615. doi:10.1007/s004150200071</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004150200071</ArticleId><ArticleId IdType="pubmed">12021952</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Aoki M, Tsuji S, et al. ; Writing Group; Edaravone (MCI-186) ALS 19 Study Group . Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505-512. doi:10.1016/S1474-4422(17)30115-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, van den Berg LH. Edaravone: a new treatment for ALS on the horizon? Lancet Neurol. 2017;16(7):490-491. doi:10.1016/S1474-4422(17)30163-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30163-1</ArticleId><ArticleId IdType="pubmed">28522180</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JM, Kim SY, Park D, Park JS. Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients. Neurol Sci. 2020;41(1):119-123. doi:10.1007/s10072-019-04055-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-04055-3</ArticleId><ArticleId IdType="pmc">PMC7223963</ArticleId><ArticleId IdType="pubmed">31471712</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham A, Nefussy B, Fainmesser Y, Ebrahimi Y, Karni A, Drory VE. Early post-marketing experience with edaravone in an unselected group of patients with ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(3-4):260-263. doi:10.1080/21678421.2019.1572191</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1572191</ArticleId><ArticleId IdType="pubmed">30784320</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortuna A, Gizzi M, Bello L, et al. ; Edaravone Study Group . Safety and efficacy of edaravone compared to historical controls in patients with amyotrophic lateral sclerosis from North-Eastern Italy. J Neurol Sci. 2019;404:47-51. doi:10.1016/j.jns.2019.06.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.06.006</ArticleId><ArticleId IdType="pubmed">31325668</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada M, Yamashita S, Ueyama H, Ishizaki M, Maeda Y, Ando Y. Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis. eNeurologicalSci. 2018;11:11-14. doi:10.1016/j.ensci.2018.05.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ensci.2018.05.001</ArticleId><ArticleId IdType="pmc">PMC6006910</ArticleId><ArticleId IdType="pubmed">29928711</ArticleId></ArticleIdList></Reference><Reference><Citation>Medical Advisory Panel and VISN Pharmacist Executives  Edaravone (Radicava) Criteria for Use. Published December 2017. Accessed January 19, 2020. https://www.pbm.va.gov/apps/VANationalFormulary</Citation></Reference><Reference><Citation>Radicava (Edaravone)&#x2013;2018. Blue Cross/Blue Shield of Rhode Island. Published June 1, 2018. Accessed February 13, 2020. https://www.bcbsri.com/sites/default/files/polices/2018%20Radicava%20%28Edaravone%29%206_1_2018.pdf</Citation></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. ; BDNF ALS Study Group (Phase III) . The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999;169(1-2):13-21. doi:10.1016/S0022-510X(99)00210-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo L, Song Z, Li X, et al. . Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis&#x2014;a systematic review and meta-analysis. Neurol Sci. 2019;40(2):235-241. doi:10.1007/s10072-018-3653-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-018-3653-2</ArticleId><ArticleId IdType="pubmed">30483992</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold N, Sohn M, Maynard C, Hynes D VIReC Technical Report 2: VA NDI Mortality Data Merge Project. VA Information Resource Center; 2006.</Citation></Reference><Reference><Citation>Emmendorfer T, Glassman PA, Moore V, Leadholm TC, Good CB, Cunningham F. Monitoring adverse drug reactions across a nationwide health care system using information technology. Am J Health Syst Pharm. 2012;69(4):321-328. doi:10.2146/ajhp110026</Citation><ArticleIdList><ArticleId IdType="doi">10.2146/ajhp110026</ArticleId><ArticleId IdType="pubmed">22302257</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson C, Heiman-Patterson T, Kittrell P, et al. . Radicava (edaravone) for amyotrophic lateral sclerosis: US experience at 1 year after launch. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(7-8):605-610. doi:10.1080/21678421.2019.1645858</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1645858</ArticleId><ArticleId IdType="pubmed">31364409</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Kim HJ, Lonjon G, Zhu Y; written on behalf of AME Big-Data Clinical Trial Collaborative Group . Balance diagnostics after propensity score matching. Ann Transl Med. 2019;7(1):16. doi:10.21037/atm.2018.12.10</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm.2018.12.10</ArticleId><ArticleId IdType="pmc">PMC6351359</ArticleId><ArticleId IdType="pubmed">30788363</ArticleId></ArticleIdList></Reference><Reference><Citation>Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509. doi:10.1080/01621459.1999.10474144</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01621459.1999.10474144</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>